WHIM syndrome pipeline
May 10, 2024
X4 Pharmaceuticals’ XOLREMDI for WHIM Syndrome: First Targeted Treatment
X4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
